ClinicalTrials.gg

Program

ABBV-932

A development code.

In AbbVie's pipeline, D3/ D2/ 5-HT1A receptor partial agonist. Its studies are mostly in Generalized Anxiety Disorder · Bipolar Disorder, led by AbbVie.

Furthest: phase 2, since Sep 18, 202410 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie103 open or runningphase 2since Sep 18, 2024Feb 13, 2023Nov 2026phase 2 · NCT06846320
  • Named in AbbVie’s own pipeline as ABBV-932, phase 2, as of Jul 30, 2026 (source).

Also a collaborator on its studies: gedeon-richter-plc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2023First study: phase 1 study in Generalized Anxiety DisorderFirst studyNCT05738850 · 104 enrolled · United States
  2. Aug 30, 2023Phase 1 study in Generalized Anxiety DisorderNCT06024239 · 72 enrolled · United States
  3. Mar 3, 2024Phase 1 study in Healthy VolunteersNCT06300580 · 11 enrolled · United Kingdom
  4. Sep 18, 2024Phase 2 study in Bipolar DisorderNCT06605599 · 161 enrolled · United States, Japan, Puerto Rico
  5. Feb 21, 2025Phase 2 study in Generalized Anxiety DisorderNCT06846320 · 315 planned · United States, Puerto Rico
  6. Feb 24, 2025Phase 1 study in Healthy VolunteerNCT06849791 · 9 enrolled · United States
  7. Apr 24, 2025Phase 1 study in Healthy VolunteerNCT06953934 · 8 enrolled · Netherlands
  8. Jun 9, 2025Phase 1 study in Healthy VolunteerNCT07024797 · 20 enrolled · China
  9. Jul 8, 2025Phase 1 study in Bipolar DisorderNCT07071532 · 20 planned · United States
  10. Sep 26, 2025Phase 2 study in Bipolar I or II DisorderNCT07220460 · 84 enrolled · United States, Puerto Rico

Ahead

  1. Nov 2026Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06846320
  2. Feb 2027Primary completion: phase 1 study in Bipolar DisorderNCT07071532
  3. Mar 2027Primary completion: phase 2 study in Bipolar I or II DisorderNCT07220460

TargetBeta

“D3/ D2/ 5-HT1A receptor partial agonist”the company's pipeline, read by Claude · source

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07220460Bipolar I or II Disorder · United States, Puerto Rico2Active, not recruitingMar 202784
NCT07071532Bipolar Disorder · United States1RecruitingFeb 202720
NCT07024797Healthy Volunteer · China1CompletedDec 8, 202520
NCT06953934Healthy Volunteer · Netherlands1CompletedSep 14, 20268
NCT06849791Healthy Volunteer · United States1CompletedMay 8, 20269
NCT06846320Generalized Anxiety Disorder · United States, Puerto Rico2RecruitingNov 2026315
NCT06605599Bipolar Disorder · United States, Japan, Puerto Rico2CompletedNov 12, 2025161
NCT06300580Healthy Volunteers · United Kingdom1CompletedMay 26, 202511
NCT06024239Generalized Anxiety Disorder · United States1CompletedMar 4, 202572
NCT05738850Generalized Anxiety Disorder · United States1CompletedMay 31, 2024104

How it is read

Names in the registry

  • “ABBV-932”, 11 entries

Codes read as this program: ABBV932.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.